Crane Biosciences

Crane Biosciences is a biotechnology company developing a non-immunogenic RNA delivery platform based on nanoparticles derived from red blood cell membranes.

By using the body's own cellular architecture as a delivery vehicle, the platform achieves substantially higher in vivo delivery efficiency to target tissues including the brain and immune cells compared to synthetic nanoparticles, while evading immune clearance.

The company uses AI to optimise targeting and applies the technology to neurodegenerative diseases and cancer.